{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:59:21Z","timestamp":1780394361882,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":629,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["SPORE MM SPORE 5P50 CA186781-04"],"award-info":[{"award-number":["SPORE MM SPORE 5P50 CA186781-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jtct.2021.06.016","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T11:31:58Z","timestamp":1624015918000},"page":"770.e1-770.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience"],"prefix":"10.1016","volume":"27","author":[{"given":"Iuliana","family":"Vaxman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eapen","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2021.06.016_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.jtct.2021.06.016_bib0002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2021.06.016_bib0003","article-title":"Getting blood out of a stone: identification and management of patients with poor hematopoietic cell mobilization","volume":"47","author":"Chen","year":"2020","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.jtct.2021.06.016_bib0004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2013.175","article-title":"Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy","volume":"49","author":"Kumar","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2021.06.016_bib0005","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bbmt.2019.11.024","article-title":"Impact of plerixafor use at different peripheral blood CD34(+) thresholds on autologous stem cell collection in patients with multiple myeloma","volume":"26","author":"Shah","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2021.06.016_bib0006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41409-020-01033-8","article-title":"Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience","volume":"56","author":"Laurent","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2021.06.016_bib0007","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbmt.2013.11.003","article-title":"Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification","volume":"20","author":"Costa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2021.06.016_bib0008","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jtct.2021.06.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102722","article-title":"Inferior prognosis in poor mobilizing myeloma patients","volume":"59","author":"Yi\u011feno\u011flu","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"10.1016\/j.jtct.2021.06.016_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102819","article-title":"A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: an Italian explorative cost analysis","volume":"59","author":"Laszlo","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"19","key":"10.1016\/j.jtct.2021.06.016_bib0011","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2021.06.016_bib0012","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2021.06.016_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10192","key":"10.1016\/j.jtct.2021.06.016_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jtct.2021.06.016_bib0015","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/1078155220920690","article-title":"Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: a cohort study and comprehensive literature review","volume":"27","author":"Almalag","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"10.1016\/j.jtct.2021.06.016_bib0016","first-page":"1041","article-title":"A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma","volume":"87","author":"Corso","year":"2002","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2021.06.016_bib0017","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","article-title":"A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients","volume":"27","author":"Fitoussi","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2021.06.016_bib0018","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2021.06.016_bib0019","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.clml.2020.04.002","article-title":"KRD-PACE mobilization for multiple myeloma patients with significant residual disease before autologous stem-cell transplantation","volume":"20","author":"Cowan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.jtct.2021.06.016_bib0020","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2021.06.016_bib0021","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2021.06.016_bib0022","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2021.06.016_bib0023","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbmt.2017.10.008","article-title":"Chemotherapy-based stem cell mobilization does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens","volume":"24","author":"Oyekunle","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2021.06.016_bib0024","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3109\/10428194.2015.1102240","article-title":"Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF","volume":"57","author":"Jang","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jtct.2021.06.016_bib0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2015.236","article-title":"A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma","volume":"51","author":"Silvennoinen","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2021.06.016_bib0026","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jca.21421","article-title":"Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma","volume":"31","author":"Lin","year":"2016","journal-title":"J Clin Apher"},{"issue":"11","key":"10.1016\/j.jtct.2021.06.016_bib0027","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/bmt.2013.80","article-title":"Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone","volume":"48","author":"Sung","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2021.06.016_bib0028","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.06.016_bib0029","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41409-020-0916-3","article-title":"Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant","volume":"55","author":"Al Saleh","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2021.06.016_bib0030","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.V98.7.2059","article-title":"Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation","volume":"98","author":"Narayanasami","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2021.06.016_bib0031","first-page":"937","article-title":"Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma","volume":"17","author":"Demirer","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2021.06.016_bib0032","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41409-021-01251-8","article-title":"Chemotherapy-based versus chemotherapy-free stem cell mobilization (\u00b1 plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis","volume":"56","author":"Lazzaro","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2021.06.016_bib0033","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41409-020-0940-3","article-title":"Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma","volume":"55","author":"Van de Wyngaert","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721010009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721010009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:13Z","timestamp":1763002813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721010009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2666636721010009"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.06.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}